Literature DB >> 25811827

Cost implications of human and automated follow-up in ambulatory care.

Eta S Berner1, Jeffrey H Burkhardt, Anantachai Panjamapirom, Midge N Ray.   

Abstract

OBJECTIVES: To compare the costs of human and automated follow-up processes in ambulatory care. STUDY
DESIGN: Analysis of costs of nurse-initiated and interactive voice response (IVR) system follow-up interventions.
METHODS: Using national cost data and data on follow-up processes and outcomes from a previous study, we examined the costs to the healthcare system and providers of developing a follow-up process using nurse-initiated telephone calls compared with calls made by an IVR.
RESULTS: Whether using nurse-initiated telephone calls or IVR calls, costs over the first 2 years of follow-up for a practice assumed to have 4800 acute care patient visits per year are approximately the same. After 2 years, IVR follow-up is approximately $9000 per year less expensive than nurse follow-up. In addition, overall cost savings are greater with IVR.
CONCLUSIONS: Follow-up of ambulatory care patients is a way to assess risks of future problems and associated costs and to improve quality of care. An automated follow-up process using IVR is more efficient than one based on nurse-initiated follow-up calls.

Entities:  

Mesh:

Year:  2014        PMID: 25811827

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  2 in total

1.  Screening for Adverse Drug Events: a Randomized Trial of Automated Calls Coupled with Phone-Based Pharmacist Counseling.

Authors:  Gordon D Schiff; Elissa Klinger; Alejandra Salazar; Jeffrey Medoff; Mary G Amato; E John Orav; Shimon Shaykevich; Enrique V Seoane; Lake Walsh; Theresa E Fuller; Patricia C Dykes; David W Bates; Jennifer S Haas
Journal:  J Gen Intern Med       Date:  2018-10-05       Impact factor: 5.128

2.  Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.

Authors:  Ted A Skolarus; Tabitha Metreger; Daniela Wittmann; Soohyun Hwang; Hyungjin Myra Kim; Robert L Grubb; Jeffrey R Gingrich; Hui Zhu; John D Piette; Sarah T Hawley
Journal:  J Clin Oncol       Date:  2019-03-29       Impact factor: 44.544

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.